Shares of MiMedx Group Inc. (NASDAQ:MDXG) traded down 1% during trading on Monday . The stock traded as low as $8.17 and last traded at $8.17, with a volume of 241,297 shares trading hands. The stock had previously closed at $8.25.

Several equities analysts recently weighed in on MDXG shares. Brean Capital reaffirmed a “buy” rating on shares of MiMedx Group in a research report on Wednesday, June 29th. Zacks Investment Research raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. First Analysis cut shares of MiMedx Group from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $14.00 to $9.00 in a research report on Wednesday, April 27th. TheStreet cut shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Monday, April 25th. Finally, Lake Street Capital dropped their price target on shares of MiMedx Group from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, April 19th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $10.89.

The stock has a market cap of $895.01 million and a PE ratio of 35.37. The company has a 50-day moving average of $7.85 and a 200-day moving average of $8.09.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Tuesday, April 26th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.01. The company had revenue of $53.40 million for the quarter, compared to the consensus estimate of $54.05 million. Equities analysts forecast that MiMedx Group Inc. will post $0.31 earnings per share for the current year.

In related news, CEO Parker H. Petit purchased 50,000 shares of MiMedx Group stock in a transaction that occurred on Thursday, May 12th. The shares were bought at an average price of $6.74 per share, for a total transaction of $337,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,919,121 shares of the company’s stock, valued at $33,154,875.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Parker H. Petit purchased 30,000 shares of MiMedx Group stock in a transaction that occurred on Tuesday, May 17th. The shares were bought at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the transaction, the chief executive officer now directly owns 4,989,121 shares of the company’s stock, valued at $34,025,805.22. The disclosure for this purchase can be found here.

Several institutional investors recently made changes to their positions in the stock. American Century Companies Inc. boosted its position in shares of MiMedx Group by 0.8% in the fourth quarter. American Century Companies Inc. now owns 608,322 shares of the company’s stock valued at $5,700,000 after buying an additional 4,722 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of MiMedx Group by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 672,248 shares of the company’s stock valued at $6,299,000 after buying an additional 29,523 shares in the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of MiMedx Group by 1.5% in the fourth quarter. Parsons Capital Management Inc. RI now owns 718,700 shares of the company’s stock valued at $6,734,000 after buying an additional 10,650 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of MiMedx Group by 19.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,041,546 shares of the company’s stock valued at $9,759,000 after buying an additional 169,102 shares in the last quarter. Finally, Russell Frank Co boosted its position in shares of MiMedx Group by 3.2% in the fourth quarter. Russell Frank Co now owns 403,005 shares of the company’s stock valued at $3,840,000 after buying an additional 12,499 shares in the last quarter.

MiMedx Group, Inc (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.